Advertisement
Organisation › Details
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. *
Start | 1983-01-01 existent | |
Group | Teva (Group) | |
Industry | DRUGS, GENERICS | |
Industry 2 | pharmaceutical | |
Person | Levin, Jeremy M. (Ovid Therapeutics 202005 CEO + Chairman of BIO before Teva + BMS + Novartis +Cadus) | |
Person 2 | Sekhri, Paul J. (eGenesis 201901– CEO before Lycera + Sanofi + Teva + TPG Biotech + Cerimon + Ariad + Sprout) | |
Region | Petah Tikwa | |
Country | Israel | |
Street | 5 Basel St., POB 3190 | |
City | 49131 Petah Tikva | |
Tel | +972-3-9267267 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | H: 10,001 to 50,00 (2011-09-15) |
Currency | USD | |
Annual sales | 21,903,000,000 (revenues, net, consolidated (2016) 2016-12-31) | |
Profit | 311,000,000 (2016-12-31) | |
Cash | 988,000,000 (2016-12-31) | |
* Document for »About Section«: Teva Pharmaceutical Industries Ltd.. (11/7/19). "Press Release: Teva Announces Appointment of New Chief Financial Officer". Jerusalem. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Teva (Group)
- [1] Rentschler Biopharma SE. (11/16/22). "Press Release: Rentschler Biopharma Appoints Christiane Bardroff as Chief Operating Officer and Member of the Executive Board". Laupheim....
- [2] Oxford Biomedica plc. (7/15/21). "Press Release: Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director". Oxford....
- [3] Almirall S.A.. (2/3/21). "Press Release: Almirall Announces Gianfranco Nazzi as New CEO"....
- [4] Teva Pharmaceutical Industries Ltd.. (11/7/19). "Press Release: Teva Announces Appointment of New Chief Financial Officer". Jerusalem....
- [5] BiomX Ltd.. (10/15/19). "Press Release: BiomX Appoints Merav Bassan as Chief Development Officer". Ness Ziona....
- [6] Foundation Medicine, Inc.. (1/7/19). "Press Release: Foundation Medicine Announces Executive Leadership Transition". Cambridge, MA....
- [7] Teva Pharmaceutical Industries Ltd.. (6/15/18). "Press Release: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache". Jerusalem....
- [8] Teva Pharmaceutical Industries Ltd.. (11/27/17). "Press Release: Teva Announces New Organization Structure and Leadership Changes". Jerusalem....
- [9] Teva Pharmaceutical Industries Ltd.. (8/3/17). "Press Relase: Teva Reports Second Quarter 2017 Financial Results". Jerusalem....
- [10] Teva Pharmaceutical Industries Ltd.. (7/31/17). "Press Relase: Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin (trastuzumab)". Incheon & Jerusalem....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top